Summary | |
---|---|
Symbol | TYMP |
Name | thymidine phosphorylase |
Aliases | gliostatin; MNGIE; endothelial cell growth factor 1 (platelet-derived); MEDPS1; MTDPS1; PDECGF; hPD-ECGF; td ...... |
Chromosomal Location | 22q13 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | - |
Domain |
PF02885 Glycosyl transferase family PF00591 Glycosyl transferase family PF07831 Pyrimidine nucleoside phosphorylase C-terminal domain |
Function |
May have a role in maintaining the integrity of the blood vessels. Has growth promoting activity on endothelial cells, angiogenic activity in vivo and chemotactic activity on endothelial cells in vitro. ; FUNCTION: Catalyzes the reversible phosphorolysis of thymidine. The produced molecules are then utilized as carbon and energy sources or in the rescue of pyrimidine bases for nucleotide synthesis. |
Biological Process |
GO:0001525 angiogenesis GO:0006206 pyrimidine nucleobase metabolic process GO:0006213 pyrimidine nucleoside metabolic process GO:0008655 pyrimidine-containing compound salvage GO:0009112 nucleobase metabolic process GO:0009116 nucleoside metabolic process GO:0009163 nucleoside biosynthetic process GO:0009164 nucleoside catabolic process GO:0019439 aromatic compound catabolic process GO:0034655 nucleobase-containing compound catabolic process GO:0043094 cellular metabolic compound salvage GO:0043097 pyrimidine nucleoside salvage GO:0043174 nucleoside salvage GO:0044270 cellular nitrogen compound catabolic process GO:0046134 pyrimidine nucleoside biosynthetic process GO:0046135 pyrimidine nucleoside catabolic process GO:0046700 heterocycle catabolic process GO:0048514 blood vessel morphogenesis GO:0072527 pyrimidine-containing compound metabolic process GO:0072528 pyrimidine-containing compound biosynthetic process GO:0072529 pyrimidine-containing compound catabolic process GO:1901136 carbohydrate derivative catabolic process GO:1901361 organic cyclic compound catabolic process GO:1901565 organonitrogen compound catabolic process GO:1901657 glycosyl compound metabolic process GO:1901658 glycosyl compound catabolic process GO:1901659 glycosyl compound biosynthetic process |
Molecular Function |
GO:0004645 phosphorylase activity GO:0008083 growth factor activity GO:0009032 thymidine phosphorylase activity GO:0016154 pyrimidine-nucleoside phosphorylase activity GO:0016757 transferase activity, transferring glycosyl groups GO:0016758 transferase activity, transferring hexosyl groups GO:0016763 transferase activity, transferring pentosyl groups |
Cellular Component | - |
KEGG |
hsa00240 Pyrimidine metabolism hsa00983 Drug metabolism - other enzymes hsa01100 Metabolic pathways |
Reactome |
R-HSA-1430728: Metabolism R-HSA-15869: Metabolism of nucleotides R-HSA-73621: Pyrimidine catabolism R-HSA-73848: Pyrimidine metabolism R-HSA-73614: Pyrimidine salvage reactions |
Summary | |
---|---|
Symbol | TYMP |
Name | thymidine phosphorylase |
Aliases | gliostatin; MNGIE; endothelial cell growth factor 1 (platelet-derived); MEDPS1; MTDPS1; PDECGF; hPD-ECGF; td ...... |
Chromosomal Location | 22q13 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between TYMP and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
Literatures describing the relation between TYMP and anti-tumor immunity in human cancer.
|
Summary | |
---|---|
Symbol | TYMP |
Name | thymidine phosphorylase |
Aliases | gliostatin; MNGIE; endothelial cell growth factor 1 (platelet-derived); MEDPS1; MTDPS1; PDECGF; hPD-ECGF; td ...... |
Chromosomal Location | 22q13 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of TYMP in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | TYMP |
Name | thymidine phosphorylase |
Aliases | gliostatin; MNGIE; endothelial cell growth factor 1 (platelet-derived); MEDPS1; MTDPS1; PDECGF; hPD-ECGF; td ...... |
Chromosomal Location | 22q13 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of TYMP in various data sets.
|
Points in the above scatter plot represent the mutation difference of TYMP in various data sets.
|
Summary | |
---|---|
Symbol | TYMP |
Name | thymidine phosphorylase |
Aliases | gliostatin; MNGIE; endothelial cell growth factor 1 (platelet-derived); MEDPS1; MTDPS1; PDECGF; hPD-ECGF; td ...... |
Chromosomal Location | 22q13 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TYMP. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | TYMP |
Name | thymidine phosphorylase |
Aliases | gliostatin; MNGIE; endothelial cell growth factor 1 (platelet-derived); MEDPS1; MTDPS1; PDECGF; hPD-ECGF; td ...... |
Chromosomal Location | 22q13 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TYMP. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TYMP. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | TYMP |
Name | thymidine phosphorylase |
Aliases | gliostatin; MNGIE; endothelial cell growth factor 1 (platelet-derived); MEDPS1; MTDPS1; PDECGF; hPD-ECGF; td ...... |
Chromosomal Location | 22q13 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TYMP. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | TYMP |
Name | thymidine phosphorylase |
Aliases | gliostatin; MNGIE; endothelial cell growth factor 1 (platelet-derived); MEDPS1; MTDPS1; PDECGF; hPD-ECGF; td ...... |
Chromosomal Location | 22q13 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of TYMP expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | TYMP |
Name | thymidine phosphorylase |
Aliases | gliostatin; MNGIE; endothelial cell growth factor 1 (platelet-derived); MEDPS1; MTDPS1; PDECGF; hPD-ECGF; td ...... |
Chromosomal Location | 22q13 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between TYMP and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | TYMP |
Name | thymidine phosphorylase |
Aliases | gliostatin; MNGIE; endothelial cell growth factor 1 (platelet-derived); MEDPS1; MTDPS1; PDECGF; hPD-ECGF; td ...... |
Chromosomal Location | 22q13 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting TYMP collected from DrugBank database. |
Details on drugs targeting TYMP.
|